Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial

Journal of the American Medical Association

Volumn 282, Issue 21, 1999, Pages 2003-2011

  Furlan, Anthony ^a   Higashida, Randall ^b   Wechsler, Lawrence ^c   Gent, Michael ^d   Rowley, Howard ^b   Kase, Carlos ^e   Pessin, Michael ^f   Ahuja, Arvind ^g   Callahan, Fred ^h   Clark, Wayne M ⁱ   Silver, Frank ^j   Rivera, Frank ^k  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g ST LUKE S MEDICAL CENTER   (United States)

^h CENTENNIAL MEDICAL CENTER   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j TORONTO WESTERN HOSPITAL   (Canada)

^k BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PROUROKINASE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECANALIZATION; STROKE; TREATMENT OUTCOME;

AGED; BRAIN ISCHEMIA; CEREBRAL ANGIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; INFUSIONS, INTRA-ARTERIAL; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; RECOMBINANT PROTEINS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033486107     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.282.21.2003     Document Type: Article

References (47)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274:1017-1025.
3. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA. 1996;276:961-966.
4. The Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335:145-150.
5. The Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischaemic stroke. Lancet. 1995;346:1509-1514.
6. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
7. Clark WM, Albers GW, for the ATLANTIS Stroke Investigators. The Atlantis rt-PA (Alteplase) Acute Stroke Trial: final results [abstract]. Stroke. 1999;30:234.
8. Muir KW, Grosset DG. Neuroprotection for acute stroke: making clinical trials work. Stroke. 1999;30: 180-182.
9. Sandercock P, Hennerici MG, Orgogozo JM, Davis SM, Gorelick PB. Mega trials versus small trials in stroke. In: Fisher M, Bogousslavsky J, eds. Current Review of Cerebrovascular Disease. Boston, Mass: Butterworth-Heinemann; 1999:217-222.
10. Gonner F, Remonda L, Mattle H, et al. Local intraarterial thrombolysis in acute ischemic stroke. Stroke. 1998;29:1894-1900.
11. del Zoppo GJ, Ferbert A, Otis S, et al. Local intraarterial fibrinolytic therapy in acute carotid territory stroke: a pilot study. Stroke. 1988;19:307-313.
12. Theron J, Courtheoux P, Casasco A, et al. Local intraarterial fibrinolysis in the carotid territory. AJNR Am J Neuroradiol. 1989;10:753-765.
13. Mori E, Tabuchi M, Yoshida T, et al. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke. 1988;19:802-812.
14. Zeumer H, Freitag HJ, Zanella F, et al. Local intraarterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology. 1993;35:159-162.
15. Hacke W, Zeumer H, Ferbert A, et al. Intraarterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke. 1988;19:1216-1222.
16. Pessin M, del Zoppo GJ, Furlan AJ. Thrombolytic treatment in acute stroke: review and update of selective topics. In: Moskowitz MA, Caplan LR, eds. Cerebrovascular Diseases: Nineteenth Princeton Stroke Conference. Boston, Mass: Butterworth-Heinemann: 1995:409-418.
17. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998;29:4-11.
18. Kasai S, Arimura H, Nishida M, Suyama T. Primary structure of single-chain pro-urokinase. J Biol Chem. 1985;260:12382-12389.
19. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood. 1986;44:217-228.
20. Tebbe U, Windeler J, Boesl I, et al. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS Study). J Am Coll Cardiol. 1995; 26:365-373.
21. Gurewich V, Liu J. Intra-arterial pro-urokinase in ischemic stroke [letter]. Stroke. 1998;29:1255.
22. Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864-870.
23. TIMI Study group. Special report: the Thrombolysis in Myocardial Infarction (TIMI) trial. N Engl J Med. 1985;312:932-936.
24. Wolfe CD, Taub NA, Woodrow BA, Burney PG. Assessment of scales of disability and handicap for stroke patients. Stroke. 1991;22:1242-1244.
25. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988; 19:604-607.
26. Furlan AJ. Natural history of atherothromboembolic occlusion of cerebral arteries: carotid versus vertebrobasilar territories. In: Hacke W, del Zoppo GJ, Hirschberg M, eds. Thrombolytic Therapy in Acute Ischemic Strote. New York, NY: Springer-Verlag; 1991: 71-76.
27. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
28. Ferguson RD, Ferguson JG. Cerebral intraarterial thrombolysis at the crossroads: is a phase III trial advisable at this time? AJNR Am J Neuroradiol. 1994; 15:1201-1216.
29. del Zoppo GJ, Higashida RT, Furlan AJ. The case for a phase III trial of cerebral intraarterial fibrinolysis. AJNR Am J Neuroradiol. 1994;15:1217-1222.
30. Moulin T, Cattin F, Crepin-Leblond T, et al. Early CT signs in acute middle cerebral artery infarction: predictive value for subsequent infarct locations and outcome. Neurology. 1996;47:366-375.
31. von Kummer R, Allen KL, Holle R, et al. Acute stroke: usefulness of early CT findings before thrombolytic therapy. Radiology. 1997;205:327-333.
32. Toni D, De Michele M, Fiorelli M, et al. Influence of hyperglycemia on infarct size and clinical outcome of acute ischemic stroke patients with intracranial arterial occlusion. J Neurol Sci. 1994;123:129-133.
33. Lodder J, Krijne-Kubat B, Broekman J. Cerebral hemorrhagic infarction at autopsy: cardiac embolic causes and the relationship to cause of death. Stroke. 1986;17:626-629.
34. Hornig CR, Dorndorf W, Agnoli AL. Hemorrhagic cerebral infarction - a prospective study. Stroke. 1986;17:179-185.
35. Okada Y, Yamaguchi T, Minematsu K, et al. Hemorrhagic transformation in cerebral embolism. Stroke. 1989;20:598-603.
36. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
37. Wolpert SM, Bruckmann H, Greenlee R, et al. Neuroradiology evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol. 1993;14:3-13.
38. Genentech, applicant. Summary basis for approval: activase TM for acute ischemic stroke. New Drug Application. PLA96-0350.
39. Tomsick T, Brott T, Barsan W, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol. 1996;17:79-85.
40. Marler JR, Jones PW, Emr M, eds. Rapid Identification and Treatment of Acute Stroke: Proceedings of a National Symposium. Bethesda, Md: National Institutes of Health; 1997. NIH Publication 97-439.
41. Ueda T, Sakaki S, Nochide I, et al. Angioplasty after intra-arterial thrombolysis for acute occlusion of intracranial arteries. Stroke. 1998;29:2568-2574.
42. Emergency Management of Stroke (EMS) Investigators. Combined intra-arterial and intravenous tPA for stroke [abstract]. Stroke. 1997;28:273.
43. Pannell R, Black J, Gurewich V. The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest. 1988;81:853-859.
44. Fisher M, Garcia JH. Evolving stroke and the ischemic penumbra. Neurology. 1996;47:884-888.
45. Baron JC, von Kummer R, del Zoppo GJ. Treatment of acute ischemic stroke - challenging the concept of a rigid and universal time window. Stroke. 1995; 26:2219-2221.
46. Fisher M, Prichard JW, Warach S. New magnetic resonance techniques for acute ischemic stroke. JAMA. 1995;274:908-911.
47. Staroselskaya IA, Baird AE, Linfante I, et al. Correlations between MR diffusion-perfusion studies and MRA in acute stroke. Neurology. 1999;52(suppl 2):455.